June 20, 2018
FDA letter updates risks of Type III endoleaks with aortic endovascular graft systems
Editor's Note
In a June 19 letter to healthcare providers, the Food & Drug Administration (FDA) says it continues to evaluate information from several sources, including manufacturers, on the risks associated with Type III endoleaks with various endovascular graft systems used for treatment of abdominal aortic aneurysms (AAAs) and aorto-iliac aneurysms.
Based on new information, the FDA says the Endologix AFX with Strata device is at greater risk for Type III endoleaks than other endovascular AAA graft systems.
Free Daily News
- Suicide Prevention Month: Hospitals prepare for new The Joint Commission suicide prevention goal, effective 2026
- Survey: Perioperative leaders adapt to supply strain, staffing pressure, ASC growth
- Gait retraining eases knee osteoarthritis pain as effectively as medication, can delay knee surgery
- OR leaders must sharpen questions, partnerships as AI reshapes perioperative care
- npj Digital Surgery opens call for research on AI, robotics in the OR
- AI in the OR can sharpen skills, but humans make the lessons stick
- Endoscopy case highlights risks of complex patients in ASCs
- Robotics and AI are redefining precision in cataract surgery
- CMS plan to phase out inpatient only list sparks debate over safety for vulnerable patients
- ACS issues new best practices for managing genitourinary trauma
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement